Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial
Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial
Five months ago, Johnson & Johnson painted sirukumab and talacotuzumab as part of a wave of blockbusters-in-waiting that would drive growth for years to come.
Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines
INDIANAPOLIS and TÜBINGEN, Germany, Oct.
Drugmakers Amneal, Impax to combine in generics push
Drugmakers Amneal, Impax to combine in generics push
(Reuters) - Amneal Pharmaceuticals LLC is buying peer Impax Laboratories Inc in an all-stock deal as it looks to add heft to its generics business and gain an edge in a tough drug pricing envi...
Pharma and medtech industries prepare for hard Brexit
Pharma and medtech industries prepare for hard Brexit
LONDON (Reuters) - Drugmakers and medical devices companies are drawing up plans to protect supply chains in case Britain crashes out of the European Union without a trade deal, and some small...
Novo Nordisk diabetes drug works; no heart risk-FDA review
Novo Nordisk diabetes drug works; no heart risk-FDA review
(Reuters) - Novo Nordisk A/S’s closely watched diabetes drug semaglutide is effective, caused no heart risk, and carried only limited risk of sight problems, a preliminary review by the U.
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
Pfizer Presents Full Results from Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib in ALK-Positive and ROS1-Positive Advanced Non-Small Cell Lung Cancer
Pfizer Inc.
Impact bags $22M to save ex-Sanofi drug from trial limbo
Impact bags $22M to save ex-Sanofi drug from trial limbo
In 2013, Sanofi was running multiple clinical trials to establish fedratinib as the cornerstone of its oncology portfolio.
ChemDiv Achieves Milestone in Viriom Collaboration on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development
ChemDiv Achieves Milestone in Viriom Collaboration on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development
ChemDiv has reached a development milestone in partnership with Viriom Inc.
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
NanOlogy™ Announces First Patient Enrolled in a Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer
WORTH, Texas & DALLAS--(BUSINESS WIRE)--NanOlogy LLC, a clinical-stage pharmaceutical development company, today announced the first patient has been enrolled in aclinical trial of NanoPac...
AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium
AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium
CAMBRIDGE, Mass.
NIH And 11 Pharmaceutical Companies Announce $215 Million Collaboration
NIH And 11 Pharmaceutical Companies Announce $215 Million Collaboration
The U.
FDA Approves Lyrica CR
FDA Approves Lyrica CR
October 12, 2017 - Pfizer Inc.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand